Literature DB >> 25590229

Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.

Louise J Murray1, Christopher M Thompson, John Lilley, Vivian Cosgrove, Kevin Franks, David Sebag-Montefiore, Ann M Henry.   

Abstract

Risks of radiation-induced second primary cancer following prostate radiotherapy using 3D-conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), flattening filter free (FFF) and stereotactic ablative radiotherapy (SABR) were evaluated. Prostate plans were created using 10 MV 3D-CRT (78 Gy in 39 fractions) and 6 MV 5-field IMRT (78 Gy in 39 fractions), VMAT (78 Gy in 39 fractions, with standard flattened and energy-matched FFF beams) and SABR (42.7 Gy in 7 fractions with standard flattened and energy-matched FFF beams). Dose-volume histograms from pelvic planning CT scans of three prostate patients, each planned using all 6 techniques, were used to calculate organ equivalent doses (OED) and excess absolute risks (EAR) of second rectal and bladder cancers, and pelvic bone and soft tissue sarcomas, using mechanistic, bell-shaped and plateau models. For organs distant to the treatment field, chamber measurements recorded in an anthropomorphic phantom were used to calculate OEDs and EARs using a linear model. Ratios of OED give relative radiation-induced second cancer risks. SABR resulted in lower second cancer risks at all sites relative to 3D-CRT. FFF resulted in lower second cancer risks in out-of-field tissues relative to equivalent flattened techniques, with increasing impact in organs at greater distances from the field. For example, FFF reduced second cancer risk by up to 20% in the stomach and up to 56% in the brain, relative to the equivalent flattened technique. Relative to 10 MV 3D-CRT, 6 MV IMRT or VMAT with flattening filter increased second cancer risks in several out-of-field organs, by up to 26% and 55%, respectively. For all techniques, EARs were consistently low. The observed large relative differences between techniques, in absolute terms, were very low, highlighting the importance of considering absolute risks alongside the corresponding relative risks, since when absolute risks are very low, large relative risks become less meaningful. A calculated relative radiation-induced second cancer risk benefit from SABR and FFF techniques was theoretically predicted, although absolute radiation-induced second cancer risks were low for all techniques, and absolute differences between techniques were small.

Entities:  

Mesh:

Year:  2015        PMID: 25590229     DOI: 10.1088/0031-9155/60/3/1237

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  29 in total

Review 1.  Radiation therapy-induced metastasis: radiobiology and clinical implications.

Authors:  Benjamin J Blyth; Aidan J Cole; Michael P MacManus; Olga A Martin
Journal:  Clin Exp Metastasis       Date:  2017-11-20       Impact factor: 5.150

2.  Risk of secondary rectal cancer and colon cancer after radiotherapy for prostate cancer: a meta-analysis.

Authors:  Zhiguo Zhu; Shankun Zhao; Yangzhou Liu; Jiamin Wang; Lianmin Luo; Ermao Li; Chaofeng Zhang; Jintai Luo; Zhigang Zhao
Journal:  Int J Colorectal Dis       Date:  2018-07-02       Impact factor: 2.571

3.  Secondary cancer risk after whole-breast radiation therapy: field-in-field versus intensity modulated radiation therapy versus volumetric modulated arc therapy.

Authors:  Emel Haciislamoglu; Yunus Cinar; Fatih Gurcan; Emine Canyilmaz; Gorkem Gungor; Adnan Yoney
Journal:  Br J Radiol       Date:  2019-07-22       Impact factor: 3.039

4.  Comparison of Radiation-Induced Secondary Malignancy Risk Between Sequential and Simultaneous Integrated Boost for the Treatment of Nasopharyngeal Carcinoma: Intensity-Modulated Radiotherapy versus Volumetric-Modulated Arc Therapy.

Authors:  Emel Haciislamoglu; Yunus Cinar; Mehmet Eren; Emine Canyilmaz; Fatih Gurcan; Lasif Serdar; Adnan Yoney
Journal:  Cancer Manag Res       Date:  2020-04-08       Impact factor: 3.989

5.  Class solutions for SABR-VMAT for high-risk prostate cancer with and without elective nodal irradiation.

Authors:  Sarah O S Osman; Prakash Jeevanandam; Nithya Kanakavelu; Denise M Irvine; Ciara A Lyons; Suneil Jain; Alan R Hounsell; Conor K McGarry
Journal:  Radiat Oncol       Date:  2016-11-24       Impact factor: 3.481

6.  Secondary cancer risk from modern external-beam radiotherapy of prostate cancer patients: Impact of fractionation and dose distribution.

Authors:  Chomporn Sitathanee; Puangpen Tangboonduangjit; Mantana Dhanachai; Sawanee Suntiwong; Pornpan Yongvithisatid; Sukanya Rutchantuk; Pimolpun Changkaew; Rattana Watjiranon; Suphalak Khachonkham; Vipa Boonkitticharoen
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

7.  Risk for second bladder and rectal malignancies from cervical cancer irradiation.

Authors:  Michalis Mazonakis; Efrosyni Lyraraki; Maria Tolia; John Damilakis
Journal:  J Appl Clin Med Phys       Date:  2021-05-21       Impact factor: 2.102

8.  Normal tissue sparing using different techniques for prostate irradiation.

Authors:  Barbara Melles-Bencsik; Tamás Pócza; Tibor Major; Péter Ágoston; Kliton Jorgo; Csaba Polgár; Csilla Pesznyák
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-09

9.  The Incidence Characteristics of Second Primary Malignancy after Diagnosis of Primary Colon and Rectal Cancer: A Population Based Study.

Authors:  Xu Guan; Yinghu Jin; Yinggang Chen; Zheng Jiang; Zheng Liu; Zhixun Zhao; Peng Yan; Guiyu Wang; Xishan Wang
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

10.  Flattening Filter-Free Beams in Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy for Sinonasal Cancer.

Authors:  Jia-Yang Lu; Jing Zheng; Wu-Zhe Zhang; Bao-Tian Huang
Journal:  PLoS One       Date:  2016-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.